Yuyu Pharma, Inc. (KRX:000220)
South Korea · Delayed Price · Currency is KRW 3,830.00
+25.00 (0.66%)
At close: Jun 10, 2026
Yuyu Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 143,520 | 140,885 | 133,147 | 137,210 | 138,881 | 115,655 |
Other Revenue | -0 | -0 | -0 | -0 | -0 | - |
| 143,520 | 140,885 | 133,147 | 137,210 | 138,881 | 115,655 | |
Revenue Growth (YoY) | 8.20% | 5.81% | -2.96% | -1.20% | 20.08% | 17.87% |
Cost of Revenue | 89,082 | 87,299 | 81,778 | 88,682 | 85,915 | 70,567 |
Gross Profit | 54,438 | 53,586 | 51,369 | 48,527 | 52,966 | 45,088 |
Selling, General & Admin | 37,434 | 36,897 | 34,190 | 37,972 | 43,028 | 37,270 |
Research & Development | 3,633 | 3,613 | 2,780 | 7,188 | 8,620 | 4,008 |
Amortization of Goodwill & Intangibles | 481.65 | 520.3 | 627.2 | 626.13 | 507.58 | 376.08 |
Other Operating Expenses | 242.63 | 239.81 | 212.88 | 219.22 | 221.25 | 258.87 |
Operating Expenses | 43,033 | 42,567 | 38,788 | 49,276 | 53,559 | 43,888 |
Operating Income | 11,405 | 11,019 | 12,582 | -748.94 | -592.11 | 1,200 |
Interest Expense | -2,230 | -2,481 | -3,218 | -2,554 | -2,581 | -2,175 |
Interest & Investment Income | 1,210 | 1,162 | 1,066 | 990.69 | 605.88 | 216.83 |
Earnings From Equity Investments | 584.98 | 571.43 | 68.58 | -493.69 | 395.07 | 548.18 |
Currency Exchange Gain (Loss) | -629.04 | -584.74 | -150.09 | -23.86 | -478.12 | 56.72 |
Other Non Operating Income (Expenses) | 1,935 | 1,078 | -892.12 | -2,592 | -852.87 | -87.18 |
EBT Excluding Unusual Items | 12,276 | 10,765 | 9,456 | -5,422 | -3,503 | -240.68 |
Gain (Loss) on Sale of Investments | -376.43 | -267.07 | -370.71 | 657.78 | 182.69 | -139.24 |
Gain (Loss) on Sale of Assets | 17.2 | 16.7 | 1,249 | 63.45 | -46.08 | -3.23 |
Asset Writedown | - | - | -349.46 | -741.5 | -444.09 | - |
Other Unusual Items | -1,914 | -1,032 | - | - | - | - |
Pretax Income | 10,003 | 9,483 | 9,985 | -5,442 | -3,810 | -383.16 |
Income Tax Expense | 535.53 | 365.96 | -304.67 | 98.44 | 615.02 | 537.13 |
Earnings From Continuing Operations | 9,467 | 9,117 | 10,289 | -5,541 | -4,425 | -920.29 |
Minority Interest in Earnings | -414.84 | -962.7 | -1,569 | -1,640 | -1,562 | -1,294 |
Net Income | 9,052 | 8,154 | 8,720 | -7,181 | -5,988 | -2,214 |
Preferred Dividends & Other Adjustments | 323.74 | 323.74 | - | -878.27 | 284.89 | 284.89 |
Net Income to Common | 8,728 | 7,830 | 8,720 | -6,303 | -6,273 | -2,499 |
Net Income Growth | 47.50% | -6.49% | - | - | - | - |
Shares Outstanding (Basic) | 16 | 16 | 17 | 16 | 17 | 16 |
Shares Outstanding (Diluted) | 20 | 20 | 17 | 16 | 17 | 16 |
Shares Change (YoY) | 21.73% | 18.27% | 4.49% | -1.89% | 3.90% | 32.81% |
EPS (Basic) | 554.39 | 492.34 | 520.00 | -387.43 | -378.31 | -156.57 |
EPS (Diluted) | 528.40 | 481.00 | 513.00 | -387.43 | -378.31 | -157.00 |
EPS Growth | 41.47% | -6.24% | - | - | - | - |
Free Cash Flow | 4,398 | 7,625 | 17,838 | -4,094 | -11,512 | -1,565 |
Free Cash Flow Per Share | 219.89 | 379.23 | 1049.38 | -251.63 | -694.28 | -98.04 |
Gross Margin | 37.93% | 38.04% | 38.58% | 35.37% | 38.14% | 38.98% |
Operating Margin | 7.95% | 7.82% | 9.45% | -0.55% | -0.43% | 1.04% |
Profit Margin | 6.08% | 5.56% | 6.55% | -4.59% | -4.52% | -2.16% |
Free Cash Flow Margin | 3.06% | 5.41% | 13.40% | -2.98% | -8.29% | -1.35% |
EBITDA | 17,027 | 16,627 | 18,248 | 4,858 | 4,435 | 5,703 |
EBITDA Margin | 11.86% | 11.80% | 13.71% | 3.54% | 3.19% | 4.93% |
D&A For EBITDA | 5,622 | 5,608 | 5,666 | 5,607 | 5,027 | 4,503 |
EBIT | 11,405 | 11,019 | 12,582 | -748.94 | -592.11 | 1,200 |
EBIT Margin | 7.95% | 7.82% | 9.45% | -0.55% | -0.43% | 1.04% |
Effective Tax Rate | 5.35% | 3.86% | - | - | - | - |
Advertising Expenses | - | 2,227 | 2,695 | 4,481 | 7,119 | 6,131 |